Top

Current Neurology and Neuroscience Reports

Published in:

01-04-2013 | Neuro-Oncology (LE Abrey, Section Editor)

Meningioma

Authors: Ali-Reza Fathi, Ulrich Roelcke

Published in: Current Neurology and Neuroscience Reports | Issue 4/2013

Abstract

Meningiomas represent the most common primary brain tumor and comprise 3 World Health Organization (WHO) grades, the most frequent being WHO grade I (90 %). Surgery is mandatory to establish the diagnosis and to remove the tumor; however, complete resection can be achieved in only <50 % of patients. Depending on the extent of resection, tumor location and the WHO grade radiation therapy can be applied. The issue of systemic treatment such as chemotherapy or targeted therapy (eg, somatostatin receptors, antiangiogenic agents) is yet not solved, particularly as current data are derived from small uncontrolled series in patients with long-standing disease and after several pretreatments. A more thorough understanding of molecular genetics, signaling pathways and prognostic factors in meningiomas should lead to the design of studies which stratify according to these factors. These studies have to be conducted in newly diagnosed patients after incomplete resection and in tumors of WHO grade II and III.

•• Kotecha RS, Pascoe EM, Rushing EJ, Rorke-Adams LB, Zwerdling T, Gao X, et al. Meningiomas in children and adolescents: a meta-analysis of individual patient data. Lancet Oncol. 2011;12(13):1229–39. Comprehensive review on epidemiologic and outcome data for meningiomas in children and adults.PubMedCrossRef

Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010;99(3):307–14.PubMedCrossRef

Oya S, Kim SH, Sade B, Lee JH. The natural history of intracranial meningiomas. J Neurosurg. 2011;114(5):1250–6.PubMed

Nakasu S, Hirano A, Shimura T, Llena JF. Incidental meningiomas in autopsy study. Surg Neurol. 1987;27(4):319–22.PubMedCrossRef

Zeidman LA, Ankenbrandt WJ, Du H, Paleologos N, Vick NA. Growth rate of non-operated meningiomas. J Neurol. 2008;255(6):891–5.PubMedCrossRef

Greenberg M. Handbook of Neurosurgery. 6th ed. New York: Thieme; 2006.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedCrossRef

Artlich A, Schmidt D. Immunohistochemical profile of meningiomas and their histological subtypes. Hum Pathol. 1990;21(8):843–9.PubMedCrossRef

Hottinger AF, Khakoo Y. Neurooncology of familial cancer syndromes. J Child Neurol. 2009;24(12):1526–35.PubMedCrossRef

10.

Zhou L, Hanemann CO. Merlin, a multi-suppressor from cell membrane to the nucleus. FEBS Lett. 2012;586(10):1403–8.PubMedCrossRef

11.

Wang X, Gong Y, Wang D, Xie Q, Zheng M, Zhou Y, et al. Analysis of gene expression profiling in meningioma: deregulated signaling pathways associated with meningioma and egfl6 overexpression in benign meningioma tissue and serum. PLoS One. 2012;7(12):e52707.PubMedCrossRef

12.

Ragel BT, Jensen RL. Aberrant signaling pathways in meningiomas. J Neurooncol. 2010;99(3):315–24.PubMedCrossRef

13.

Mawrin C, Perry A. Pathological classification and molecular genetics of meningiomas. J Neurooncol. 2010;99(3):379–91.PubMedCrossRef

14.

Gabeau-Lacet D, Aghi M, Betensky RA, Barker FG, Loeffler JS, Louis DN. Bone involvement predicts poor outcome in atypical meningioma. J Neurosurg. 2009;111(3):464–71.PubMedCrossRef

15.

Pravdenkova S, Al-Mefty O, Sawyer J, Husain M. Progesterone and estrogen receptors: opposing prognostic indicators in meningiomas. J Neurosurg. 2006;105(2):163–73.PubMedCrossRef

16.

Hasseleid BF, Meling TR, Ronning P, Scheie D, Helseth E. Surgery for convexity meningioma: Simpson Grade I resection as the goal. J Neurosurg. 2012;117(6):999–1006.PubMedCrossRef

17.

Black PM, Morokoff AP, Zauberman J. Surgery for extra-axial tumors of the cerebral convexity and midline. Neurosurgery. 2008;62(6 Suppl 3):1115–21. discussion 21–3.PubMed

18.

Yang SY, Park CK, Park SH, Kim DG, Chung YS, Jung HW. Atypical and anaplastic meningiomas: prognostic implications of clinicopathological features. J Neurol Neurosurg Psychiatry. 2008;79(5):574–80.PubMedCrossRef

19.

Jaaskelainen J. Seemingly complete removal of histologically benign intracranial meningioma: late recurrence rate and factors predicting recurrence in 657 patients. A multivariate analysis. Surg Neurol. 1986;26(5):461–9.PubMedCrossRef

20.

• Tseng KY, Chung MH, Sytwu HK, Lee HM, Chen KY, Chang C, et al. Osteopontin expression is a valuable marker for prediction of short-term recurrence in WHO grade I benign meningiomas. J Neurooncol. 2010;100(2):217–23. Osteopontin represents an integrin-binding protein and constitutes a prognostic factor which relates to progression-free survival within the histopathologic ‘entity’ of WHO I meningiomas.PubMedCrossRef

21.

Saloner D, Uzelac A, Hetts S, Martin A, Dillon W. Modern meningioma imaging techniques. J Neurooncol. 2010;99(3):333–40.PubMedCrossRef

22.

Omay SB, Barnett GH. Surgical navigation for meningioma surgery. J Neurooncol. 2010;99(3):357–64.PubMedCrossRef

23.

Hoover JM, Morris JM, Meyer FB. Use of preoperative magnetic resonance imaging T1 and T2 sequences to determine intraoperative meningioma consistency. Surg Neurol Int. 2011;2:142.PubMedCrossRef

24.

Osawa T, Tosaka M, Nagaishi M, Yoshimoto Y. Factors affecting peritumoral brain edema in meningioma: special histological subtypes with prominently extensive edema. J Neurooncol. 2012;111:49–57.PubMedCrossRef

25.

Regelsberger J, Hagel C, Emami P, Ries T, Heese O, Westphal M. Secretory meningiomas: a benign subgroup causing life-threatening complications. Neuro Oncol. 2009;11(6):819–24.PubMedCrossRef

26.

Qi ST, Liu Y, Pan J, Chotai S, Fang LX. A radiopathological classification of dural tail sign of meningiomas. J Neurosurg. 2012;117(4):645–53.PubMedCrossRef

27.

Jolapara M, Kesavadas C, Radhakrishnan VV, Thomas B, Gupta AK, Bodhey N, et al. Role of diffusion tensor imaging in differentiating subtypes of meningiomas. J Neuroradiol. 2010;37(5):277–83.PubMedCrossRef

28.

Chang V, Narang J, Schultz L, Issawi A, Jain R, Rock J, et al. Computeraided volumetric analysis as a sensitive tool for the management of incidental meningiomas. Acta Neurochir (Wien). 2012;154(4):589–97. discussion 97.CrossRef

29.

Fathi AR, Marbacher S, Lukes A. Cost-effective patient-specific intraoperative molded cranioplasty. J Craniofac Surg. 2008;19(3):777–81.PubMedCrossRef

30.

Rubin G, Herscovici Z, Laviv Y, Jackson S, Rappaport ZH. Outcome of untreated meningiomas. Isr Med Assoc J. 2011;13(3):157–60.PubMed

31.

Quinones-Hinojosa A, Kaprealian T, Chaichana KL, Sanai N, Parsa AT, Berger MS, et al. Pre-operative factors affecting resectability of giant intracranial meningiomas. Can J Neurol Sci. 2009;36(5):623–30.PubMed

32.

Carli DF, Sluzewski M, Beute GN, van Rooij WJ. Complications of particle embolization of meningiomas: frequency, risk factors, and outcome. AJNR Am J Neuroradiol. 2010;31(1):152–4.PubMedCrossRef

33.

Afshar-Oromieh A, Giesel FL, Linhart HG, Haberkorn U, Haufe S, Combs SE, et al. Detection of cranial meningiomas: comparison of (6)(8)Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging. 2012;39(9):1409–15.PubMedCrossRef

34.

Gehler B, Paulsen F, Oksuz MO, Hauser TK, Eschmann SM, Bares R, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56.PubMedCrossRef

35.

Thorwarth D, Muller AC, Pfannenberg C, Beyer T. Combined PET/MR imaging using (68)Ga-DOTATOC for radiotherapy treatment planning in meningioma patients. Recent Results Cancer Res. 2012;194:425–39.CrossRef

36.

Sughrue ME, Rutkowski MJ, Aranda D, Barani IJ, McDermott MW, Parsa AT. Treatment decision making based on the published natural history and growth rate of small meningiomas. J Neurosurg. 2010;113(5):1036–42.PubMedCrossRef

37.

Yano S, Kuratsu J. Indications for surgery in patients with asymptomatic meningiomas based on an extensive experience. J Neurosurg. 2006;105(4):538–43.PubMedCrossRef

38.

Chamoun R, Krisht KM, Couldwell WT. Incidental meningiomas. Neurosurg Focus. 2011;31(6):E19.PubMedCrossRef

39.

Dirks MS, Butman JA, Kim HJ, Wu T, Morgan K, Tran AP, et al. Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. J Neurosurg. 2012;117(1):109–17.PubMedCrossRef

40.

Goutagny S, Bah AB, Henin D, Parfait B, Grayeli AB, Sterkers O, et al. Longterm follow-up of 287 meningiomas in neurofibromatosis type 2 patients: clinical, radiological, and molecular features. Neuro Oncol. 2012;14(8):1090–6.PubMedCrossRef

41.

Adachi K, Kawase T, Yoshida K, Yazaki T, Onozuka S. ABC Surgical Risk Scale for skull base meningioma: a new scoring system for predicting the extent of tumor removal and neurological outcome. Clinical article. J Neurosurg. 2009;111(5):1053–61.PubMedCrossRef

42.

Gerlach R, Raabe A, Scharrer I, Meixensberger J, Seifert V. Post-operative hematoma after surgery for intracranial meningiomas: causes, avoidable risk factors and clinical outcome. Neurol Res. 2004;26(1):61–6.PubMedCrossRef

43.

• Strassner C, Buhl R, Mehdorn HM. Recurrence of intracranial meningiomas: did better methods of diagnosis and surgical treatment change the outcome in the last 30 years? Neurol Res. 2009;31(5):478–82. With better operating modalities and additional treatment with radiation and gamma knife, the mortality decreased significantly from 12 % to 3 % and the outcome of the patients is still improving, so that even elderly patients can undergo surgical treatment with minor risks.PubMedCrossRef

44.

Al-Mefty O, Holoubi A, Rifai A, Fox JL. Microsurgical removal of suprasellar meningiomas. Neurosurgery. 1985;16(3):364–72.PubMedCrossRef

45.

Kim EH, Cho JM, Chang JH, Kim SH, Lee KS. Application of intraoperative indocyanine green videoangiography to brain tumor surgery. Acta Neurochir (Wien). 2011;153(7):1487–95. discussion 94–5.CrossRef

46.

Coluccia D, Fandino J, Fujioka M, Cordovi S, Muroi C, Landolt H. Intraoperative 5-aminolevulinic-acid-induced fluorescence in meningiomas. Acta Neurochir (Wien). 2010;152(10):1711–9.CrossRef

47.

Bekelis K, Valdes PA, Erkmen K, Leblond F, Kim A, Wilson BC, et al. Quantitative and qualitative 5-aminolevulinic acid-induced protoporphyrin IX fluorescence in skull base meningiomas. Neurosurg Focus. 2011;30(5):E8.PubMed

48.

Soleman J, Fathi AR, Marbacher S, Fandino J. The role of intraoperative magnetic resonance imaging in complex meningioma surgery magnetic resonance imaging. Magnetic Resonance Imaging. 2012;In Press [accepted].

49.

Solheim O, Selbekk T, Lindseth F, Unsgard G. Navigated resection of giant intracranial meningiomas based on intraoperative 3D ultrasound. Acta Neurochir (Wien). 2009;151(9):1143–51.CrossRef

50.

Marbacher S, Coluccia D, Fathi AR, Andereggen L, Beck J, Fandino J. Intraoperative patient-specific reconstruction of partial bone flap defects after convexity meningioma resection. World Neurosurg. 2013;79(1):124–30.PubMedCrossRef

51.

Dehdashti AR, Ganna A, Witterick I, Gentili F. Expanded endoscopic endonasal approach for anterior cranial base and suprasellar lesions: indications and limitations. Neurosurgery. 2009;64(4):677–87. discussion 87–9.PubMedCrossRef

52.

Fatemi N, Dusick JR, de Paiva Neto MA, Malkasian D, Kelly DF. Endonasal versus supraorbital keyhole removal of craniopharyngiomas and tuberculum sellae meningiomas. Neurosurgery. 2009;64(5 Suppl 2):269–84. discussion 84–6.PubMed

53.

Komotar RJ, Starke RM, Raper DM, Anand VK, Schwartz TH. Endoscopic endonasal versus open transcranial resection of anterior midline skull base meningiomas. World Neurosurg. 2012;77(5–6):713–24.PubMedCrossRef

54.

Schroeder HW, Hickmann AK, Baldauf J. Endoscope-assisted microsurgical resection of skull base meningiomas. Neurosurg Rev. 2011;34(4):441–55.PubMedCrossRef

55.

Bledsoe JM, Link MJ, Stafford SL, Park PJ, Pollock BE. Radiosurgery for large-volume (> 10 cm3) benign meningiomas. J Neurosurg. 2010;112(5):951–6.PubMedCrossRef

56.

Bloch O, Kaur G, Jian BJ, Parsa AT, Barani IJ. Stereotactic radiosurgery for benign meningiomas. J Neurooncol. 2012;107(1):13–20.PubMedCrossRef

57.

Flannery TJ, Kano H, Lunsford LD, Sirin S, Tormenti M, Niranjan A, et al. Long-term control of petroclival meningiomas through radiosurgery. J Neurosurg. 2010;112(5):957–64.PubMedCrossRef

58.

Astner ST, Theodorou M, Dobrei-Ciuchendea M, Auer F, Kopp C, Molls M, et al. Tumor shrinkage assessed by volumetric MRI in the long-term follow-up after stereotactic radiotherapy of meningiomas. Strahlenther Onkol. 2010;186(8):423–9.PubMedCrossRef

59.

Kondziolka D, Madhok R, Lunsford LD, Mathieu D, Martin JJ, Niranjan A, et al. Stereotactic radiosurgery for convexity meningiomas. J Neurosurg. 2009;111(3):458–63.PubMedCrossRef

60.

Kondziolka D, Mathieu D, Lunsford LD, Martin JJ, Madhok R, Niranjan A, et al. Radiosurgery as definitive management of intracranial meningiomas. Neurosurgery. 2008;62(1):53–8. discussion 8–60.PubMedCrossRef

61.

Stessin AM, Schwartz A, Judanin G, Pannullo SC, Boockvar JA, Schwartz TH, et al. Does adjuvant external-beam radiotherapy improve outcomes for nonbenign meningiomas? A Surveillance, Epidemiology, and End Results (SEER)-based analysis. J Neurosurg. 2012;117(4):669–75.PubMedCrossRef

62.

Askoxylakis V, Zabel-du Bois A, Schlegel W, Debus J, Huber P, Milker-Zabel S. Patterns of failure after stereotactic radiotherapy of intracranial meningioma. J Neurooncol. 2010;98(3):367–72.PubMedCrossRef

63.

Attia A, Chan MD, Mott RT, Russell GB, Seif D, Daniel Bourland J, et al. Patterns of failure after treatment of atypical meningioma with gamma knife radiosurgery. J Neurooncol. 2012;108(1):179–85.PubMedCrossRef

64.

•• Santacroce A, Walier M, Regis J, Liscak R, Motti E, Lindquist C, et al. Longterm tumor control of benign intracranial meningiomas after radiosurgery in a series of 4565 patients. Neurosurgery. 2012;70(1):32–9. discussion 9. One of the largest series with gamma knife treatment of benign meningiomas (5300 treated tumors) reported on 5- and 10-year progression-free survival rates of 95.2 % and 88.6 %, respectively.PubMedCrossRef

65.

Henze M, Dimitrakopoulou-Strauss A, Milker-Zabel S, Schuhmacher J, Strauss LG, Doll J, et al. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas. J Nucl Med. 2005;46(5):763–9.PubMed

66.

Schulz S, Pauli SU, Handel M, Dietzmann K, Firsching R, Hollt V. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6(5):1865–74.PubMed

67.

Florio T. Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci. 2008;13(1):822–40.PubMedCrossRef

68.

Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146(5):707–16.PubMedCrossRef

69.

Bartolomei M, Bodei L, De Cicco C, Grana CM, Cremonesi M, Botteri E, et al. Peptide receptor radionuclide therapy with (90)Y-DOTATOC in recurrent meningioma. Eur J Nucl Med Mol Imaging. 2009;36(9):1407–16.PubMedCrossRef

70.

• Kreissl MC, Hanscheid H, Lohr M, Verburg FA, Schiller M, Lassmann M, et al. Combination of peptide receptor radionuclide therapy with fractionated external beam radiotherapy for treatment of advanced symptomatic meningioma. Radiat Oncol. 2012;7:99. ‘Upfront’ use of ¹⁷⁷ Lu-DOTATOC in newly diagnosed meningioma WHO I.PubMedCrossRef

71.

Mason WP, Gentili F, Macdonald DR, Hariharan S, Cruz CR, Abrey LE. Stabilization of disease progression by hydroxyurea in patients with recurrent or unresectable meningioma. J Neurosurg. 2002;97(2):341–6.PubMedCrossRef

72.

Chamberlain MC. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma. J Neurooncol. 2012;107(2):315–21.PubMedCrossRef

73.

Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatmentresistant recurrent meningioma. Neurology. 2004;62(7):1210–2.PubMedCrossRef

74.

Goodwin JW, Crowley J, Eyre HJ, Stafford B, Jaeckle KA, Townsend JJ. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a Southwest Oncology Group study. J Neurooncol. 1993;15(1):75–7.PubMedCrossRef

75.

Grunberg SM, Weiss MH, Russell CA, Spitz IM, Ahmadi J, Sadun A, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006;24(8):727–33.PubMedCrossRef

76.

Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007;69(10):969–73.PubMedCrossRef

77.

Johnson DR, Kimmel DW, Burch PA, Cascino TL, Giannini C, Wu W, et al. Phase II study of subcutaneous octreotide in adults with recurrent or progressive meningioma and meningeal hemangiopericytoma. Neuro Oncol. 2011;13(5):530–5.PubMedCrossRef

78.

Nayak L, Iwamoto FM, Rudnick JD, Norden AD, Lee EQ, Drappatz J, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012;109(1):187–93.PubMedCrossRef

79.

Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63–70.PubMedCrossRef

80.

Horak P, Wohrer A, Hassler M, Hainfellner J, Preusser M, Marosi C. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis. J Neurooncol. 2012;109(2):323–30.PubMedCrossRef

81.

Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010;96(2):211–7.PubMedCrossRef

Title: Meningioma
Authors: Ali-Reza Fathi
Ulrich Roelcke
Publication date: 01-04-2013
Publisher: Current Science Inc.
Published in: Current Neurology and Neuroscience Reports / Issue 4/2013
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI: https://doi.org/10.1007/s11910-013-0337-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Meningioma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Phenotypic Spectrum of Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Daytime Sleepiness and Myotonic Dystrophy

Agrypnia Excitata

Vertigo as a Migraine Phenomenon

Nontraumatic Subarachnoid Hemorrhage of the Convexity

Chronopharmacology of Anti-Convulsive Therapy